Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
6461.TWO
STRONG SELLREMOVEIntech Biopharm Corporation · Healthcare · Taiwan · $84M · Avg Vol: $102K/d
Intech Biopharm is a small-cap specialty pharma firm lacking the scale, regulatory moat, and high utilization required to benefit from our CDMO Pricing Power theme.
COMPANY DESCRIPTION
Intech Biopharm Corporation is a biotechnology company specializing in the development of respiratory medicines using advanced metered-dose inhaler (MDI) technology. The company focuses on generic and 505(b)(2) hybrid drug development, targeting asthma and chronic obstructive pulmonary disease (COPD). Its competitive moat is established through proprietary formulation technologies and specialized manufacturing facilities that meet global GMP standards.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 0.7M | 0.8M | 1.3M | 3.4M | 65.7% |
| EPS | -0.09 | -0.09 | -0.09 | -0.08 | — | — |
| Shares | — | 122.0M | 139.7M | 140.3M | 178.4M | +46.2% |
| Debt | — | 44.5M | 45.3M | 37.5M | 37.6M | -5.5% |
| Equity | — | 32.6M | 36.9M | 25.7M | 34.8M | 2.2% |
| Op CF | — | -6.0M | -6.4M | -8.5M | -11.4M | — |
| Inv CF | — | -6.4M | -7.5M | 13.3M | -6.2M | — |
| Fin CF | — | 7.5M | 14.3M | -1.0M | 11.9M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6461.TWO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 6461.TWO | Intech Biopharm Corporation(you) | $84M | 6 | STRONG SELL |
| 6885.TW | BRIM Biotechnology, Inc. | $91M | 9 | STRONG SELL |
| 6657.TW | Energenesis Biomedical CO.,LTD. | $101M | 8 | STRONG SELL |
| MENS | Jyong Biotech Ltd. | $121M | 4 | STRONG SELL |
| 6733.TWO | BioGend Therapeutics Co., Ltd. | $102M | 12 | STRONG SELL |
| 4174.TWO | OBI Pharma, Inc. | $116M | 1 | STRONG SELL |
| 4168.TWO | GlycoNex Incorporation | $91M | 17 | STRONG SELL |
| 4178.TW | StemCyte International, Ltd. | $117M | 12 | STRONG SELL |
| 4726.TWO | Mycenax Biotech Inc. | $160M | 5 | STRONG SELL |
| 6838.TW | Formosa Pharmaceuticals, Inc. | $116M | 15 | STRONG SELL |
Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%